Related Experiment Videos
Structural change in dopamine D2 receptor gene in a patient with neuroleptic malignant syndrome
1Clinical Neurogenetics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD 20892, USA.
Abstract:
Dysfunction of the dopaminergic system has been suggested as a pathogenic mechanism in neuroleptic malignant syndrome. Therefore, we examined the complete coding sequences of the dopamine D2 receptor (DRD2) gene for structural abnormalities in 12 patients with a history of NMS, including two cases of familial NMS. Mutational analysis was performed by denaturing gradient gel electrophoresis (DGGE), a highly sensitive technique for detecting sequences differences. We found in one patient with a history of NMS a nucleotide substitution at codon 310 (CCG-->TCG) of exon 7 of the DRD2 gene which predicts the replacement of proline to serine in the third cytoplasmic loop of the receptor, a part of the receptor that interacts with G-proteins. A larger series of patients with NMS needs to be investigated to establish whether this allele is associated with an increased susceptibility to NMS.
Insights
Researchers investigated the dopamine D2 receptor (DRD2) gene in neuroleptic malignant syndrome (NMS) patients. A specific DRD2 gene mutation was found in one NMS patient, suggesting a potential link to NMS susceptibility.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Neuroleptic malignant syndrome (NMS) is a severe reaction to antipsychotic medications.
- Dopaminergic system dysfunction is a proposed mechanism in NMS pathogenesis.
Purpose of the Study:
- To investigate the dopamine D2 receptor (DRD2) gene for structural abnormalities in patients with a history of NMS.
- To explore potential genetic links between DRD2 gene variations and NMS susceptibility.
Main Methods:
- Analysis of complete coding sequences of the DRD2 gene.
- Utilized denaturing gradient gel electrophoresis (DGGE) for mutational analysis.
- Studied 12 NMS patients, including familial cases.
Main Results:
- Identified a nucleotide substitution (CCG-->TCG) at codon 310 in exon 7 of the DRD2 gene in one NMS patient.
- This substitution predicts a proline to serine replacement in the receptor's third cytoplasmic loop, affecting G-protein interaction.
- This specific allele was found in one patient with a history of NMS.
Conclusions:
- A potential association between a specific DRD2 gene allele and increased susceptibility to NMS is suggested.
- Further investigation in a larger cohort of NMS patients is warranted to confirm this association.
- This finding contributes to understanding the genetic underpinnings of NMS.